Your browser doesn't support javascript.
loading
Similar effectiveness of R-CHOP-14 and -21 in diffuse large B-cell lymphoma-data from the prospective German Tumour Registry Lymphatic Neoplasms.
Knauf, Wolfgang; Abenhardt, Wolfgang; Mohm, Johannes; Rauh, Jacqueline; Harde, Johanna; Kaiser-Osterhues, Anja; Jänicke, Martina; Marschner, Norbert.
Afiliación
  • Knauf W; Centrum Hämatologie/Onkologie Bethanien, Frankfurt, Germany.
  • Abenhardt W; MVZ Onkologie im Elisenhof, München, Germany.
  • Mohm J; Onkologische Gemeinschaftspraxis, Dresden, Germany.
  • Rauh J; GIM Gemeinschaftspraxis, Innere Medizin, Witten, Germany.
  • Harde J; Statistics, iOMEDICO, Freiburg, Germany.
  • Kaiser-Osterhues A; Medical Department, iOMEDICO, Freiburg, Germany.
  • Jänicke M; Clinical Epidemiology and Health Economics, iOMEDICO, Freiburg, Germany.
  • Marschner N; Praxis für Interdisziplinäre Onkologie und Hämatologie, Freiburg, Germany.
Eur J Haematol ; 103(5): 460-471, 2019 Nov.
Article en En | MEDLINE | ID: mdl-31314918
OBJECTIVES: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is the standard therapy for patients with previously untreated diffuse large B-cell lymphomas (DLBCL). Dose-dense two-weekly 'R-CHOP-14' was not superior over three-weekly 'R-CHOP-21' in randomised clinical trials (RCTs). We present real-world data on effectiveness of R-CHOP-14 and R-CHOP-21 in patients with DLBCL treated in German routine practice. METHODS: We identified 582 patients with DLBCL treated with R-CHOP-14 or R-CHOP-21 in 92 sites from the prospective clinical cohort study Tumour Registry Lymphatic Neoplasms. Patients' schedules were classified by (a) length of the initial first cycle and (b) length of cycles 1-4. RESULTS: About 55% of patients received R-CHOP-21, 45% R-CHOP-14, in median 6 cycles. 51% and 55% of patients, respectively, were able to continue their initial R-CHOP-14 and R-CHOP-21 schedule. While most characteristics between the patient cohorts were similar, patients receiving R-CHOP-21 presented slightly more often with tumour stage I and lower IPI risk. 3-year overall survival of patients with R-CHOP-14 and R-CHOP-21 did not differ: 84% vs 84% (first cycle), 87% vs 89% (cycles 1-4). CONCLUSIONS: Patients with DLBCL in Germany are slightly more likely to receive R-CHOP-21 than R-CHOP-14. Both schedules are similarly effective in routine practice confirming the results from RCTs.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Sistema de Registros / Linfoma de Células B Grandes Difuso Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Eur J Haematol Asunto de la revista: HEMATOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Sistema de Registros / Linfoma de Células B Grandes Difuso Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Eur J Haematol Asunto de la revista: HEMATOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido